Organization: Merck

Brain Canada & CQDM fund AbCellera’s cell screening platform technology

AbCellera Biologics Inc and the Univ of British Columbia (UBC) received non-dilutive funding of $1 million from pharma-based consortium CQDM and charitable organization Brain Canada Foundation to advance a discovery platform for next-generation antibody therapeutics. With the additional contribution of $450,000 from AbCellera, the program will leverage AbCellera’s high throughput, single-cell screening platform to allow rapid…

Merck to acquire Burlington-based Natrix Separations

Merck, Darmstadt Germany, is acquiring Natrix Separations Inc, Burlington ON, a provider of hydrogel membrane products used to eliminate impurities during bioprocessing and accelerate the production of monoclonal antibodies and vaccines. Natrix markets both an anion exchange membrane and cation exchange membrane and is developing additional products to enable a fully single-use, full-scale biological purification…

From mobile labs to Ebola vaccines

When faced with an anthrax scare in New Brunswick, scientists from the National Microbiology Laboratory (NML) in Winnipeg rushed out with their equipment on hand. The success of this mission inspired NML to create the world’s first mobile lab. Now the concept is spreading worldwide.

CDRD, MNI and Merck join forces to develop new therapeutics

Two research institutes and a multinational pharmaceutical firm are partnering to launch NeuroCDRD, a novel drug development platform that aims to accelerate the development of therapeutics for debilitating neurological diseases such as Parkinson’s disease and amyotrophic lateral sclerosis. The Centre for Drug Research and Development (CDRD) will contribute its translational expertise while the Montreal Neurological…